Pillstats
Rx only · Tablet, Film Coated · Oral

Dolutegravir Sodium

Brands: Tivicay · Dolutegravir Sodium

2 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US4 NDCs
2 active makers
UKComing
soon
CAComing
soon
AUComing
soon
EUComing
soon
RxCUI (US)1433868
US makers2 labelers
Packages4
DEA / ScheduleNone

US acquisition costNADAC · per unit

Average across 1 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.

$22.33$44.66$66.98$89.31Jan 2026Jun 2026Jul 2026
$77.610
Latest avg · Jul 22, 2026
-0%
Since Jan 1, 2026
2
Active US suppliers
100%
Top-2 supplier share*

Medicaid dispensing volumeSDUD · per quarter

Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.

14K29K43K57K2025 Q12025 Q22025 Q32025 Q42026 Q1
39K
Rx · 2026 Q1
1.4M
Units dispensed
-21%
Rx vs. year ago
5
Quarters · since 2025 Q1

Who makes it2 active · 0 exited

US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.

LabelerTypePackagesStatus
ViiV Healthcare Companyunknown3SUPPLYING
St. Mary's Medical Park Pharmacyunknown1SUPPLYING

Regulatory & supply eventsFDA · US

Shortages, recalls, and registration changes attached to this drug concept.

  • May 17, 2024
    RECALLRecall (Class III): Tivicay PD (dolutegravir) 5mg Tablets for Oral Suspension, 60-count bottles, Each carton contains one bottle of 60 tabl…

    Labeling: Incorrect Lot and/or Expiration Date: The carton has incorrect expiration of 2026-MAY*, whereas the correct expiration date, which is on the tablet bottle label, is 2025-APR. — Recalling firm: GlaxoSmithKline LLC — Nationwide within the United States

  • May 13, 2022
    RECALLRecall (Class III): Tivicay (dolutegravir) Tablets 50 mg, 30-count Bottle, Rx Only, Manufactured for: ViiV Healthcare RTP, NC 27709, NDC 49…

    Labeling: incorrect or missing lot and/or expiration date. An incorrect expiration date was printed on the product labeling with an expiration date of January 2027, whereas the correct expiration date is September 2026. — Recalling firm: GlaxoSmithKline LLC — Nationwide in the U.S.

  • Feb 11, 2014
    RECALLRecall (Class III): Tivicay (dolutegravir) Tablets 50 mg, 30 Tablet Bottles, Rx Only. Manufactured for: ViiV Health, TRP, NC 27709; by: Gl…

    Cross Contamination with Other Products: Product contains Promacta (eltrombopag). — Recalling firm: Viiv Healthcare Company — Nationwide including Puerto Rico